2026 ISPE AI in Life Sciences Summit: Practical Guide to Measuring Large Language Models (LLMs)

Why It Matters

Rigorous, regulator‑ready validation of LLMs lowers failure risk and unlocks AI’s value in pharma, accelerating innovation while ensuring compliance.

Key Takeaways

• Over 90% of AI projects fail due to testing gaps
• Objective metrics are essential for LLM validation in pharma
• Regulatory compliance requires documented evidence of model performance
• Practical frameworks can turn AI “lemons” into reliable agents
• Continuous monitoring ensures models stay effective with real-world data

Summary

The ISPE AI in Life Sciences Summit session tackled how pharmaceutical companies can rigorously measure large language models (LLMs) and AI agents for regulated use. It highlighted the stark reality that more than 90% of AI initiatives stumble because they lack objective testing and clear evaluation criteria.

Presenters emphasized that objective, quantitative metrics—not gut feel—are crucial to prove that an LLM performs reliably on real‑world data and can sustain that performance over time. They outlined a step‑by‑step framework for establishing baseline benchmarks, stress‑testing models, and generating the documentation regulators and quality teams demand.

A key quote underscored the pragmatic tone: “I’m not going to tell you AI will perform miracles; we need to measure the lemon and prove it works.” The session offered concrete examples of validation datasets, performance dashboards, and control‑chart techniques to turn experimental models into compliant production assets.

The implications are clear: firms that adopt these measurement practices can reduce project failure rates, accelerate time‑to‑value, and meet stringent compliance standards, positioning AI as a reliable driver of drug development and operational efficiency.